-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Biogen, Raises Price Target to $290

Benzinga·10/29/2026 11:01:58
Listen to the news
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.